United States - English - NLM (National Library of Medicine)

target corporation - petrolatum 41% - skin protectant - temporarily protects: minor cuts, scrapes, burns - temporarily protects and helps relieve chapped or cracked skin and lips - helps protect from the drying effects of wind and cold weather - helps treat and prevent diaper rash - protects chafed skin due to diaper rash and helps seal out wetness - condition worsens - symptoms last more than 7 days or clear up and occur again within a few days - deep or puncture wounds - animal bites - serious burn

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة نهر الاردن للصناعات الدوائية - jordan river pharmaceutical industries - rosuvastatin calcium 41.6 mg/1 tab - 41.6 mg/1 tab

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع الأدوية المهني - professional drug store - dimeticone 41.2 mg/ml - 41.2 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

regional health ltd - barium sulfate 41.3091%{relative} (2% w/w final reconstituted strength) - powder for oral suspension - 41.9% w/w - active: barium sulfate 41.3091%{relative} (2% w/w final reconstituted strength) excipient: carmellose sodium carrageenan citric acid ethyl vanillin artificial candied sugar flavour powder 231410 orange flavour 17-42-8187 polyoxyethylene glyceryl mono-oleate saccharin sodium simeticone sodium citrate dihydrate sorbitol xanthan gum

Canada - English - Health Canada

squibb diagnostics, division of bristol-myers squibb canada inc. - iopamidol - liquid - 41% - iopamidol 41% - roentgenography

United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 4 g in 60 ml - mesalamine rectal suspension enema is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. mesalamine rectal suspension enema is contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, sulfites or any other component of this medication.

United States - English - NLM (National Library of Medicine)

ther-rx corporation - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1.53 mg - evamist is contraindicated in women with any of the following conditions:       • undiagnosed abnormal genital bleeding       • known, suspected, or history of cancer of the breast       • known or suspected estrogen-dependent neoplasia       • active dvt, pe, or history of these conditions       • active arterial thromboembolic disease (for example, stroke and mi), or history of these conditions       • known anaphylactic reaction or angioedema with evamist       • known liver impairment or disease       • known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders       • known or suspected pregnancy evamist should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. evamist should not be used during lactation. estrogen administration to nursing women has been shown to decrease

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - temozolomide (unii: yf1k15m17y) (temozolomide - unii:yf1k15m17y) - temozolomide 5 mg - temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. temozolomide capsules are indicated for the treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. temozolomide is contraindicated in patients who have a history of hypersensitivity reaction (such as urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and stevens-johnson syndrome) to any of its components. temozolomide is also contraindicated in patients who have a history of hypersensitivity to dacarbazine (dtic), since both drugs are metabolized to 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (mtic). pregnancy category d. see warnings and precautions section. temozolomide can cause fetal harm when administered to a pregnant woman. five consecutive days of oral temozolom

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - varicella-zoster virus strain oka/merck live antigen (unii: gpv39zgd8c) (varicella-zoster virus strain oka/merck live antigen - unii:gpv39zgd8c) - varicella-zoster virus strain oka/merck live antigen 19400 [pfu] in 0.65 ml - zostavax® is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. limitations of use of zostavax: - zostavax is not indicated for the treatment of zoster or postherpetic neuralgia (phn). - zostavax is not indicated for prevention of primary varicella infection (chickenpox). do not administer zostavax to individuals with a history of anaphylactic/anaphylactoid reaction to gelatin, neomycin or any other component of the vaccine. neomycin allergy manifested as contact dermatitis is not a contraindication to receiving this vaccine. {1} do not administer zostavax to individuals who are immunodeficient or immunosuppressed due to disease or therapy, as serious or fatal disseminated vaccine strain varicella-zoster virus disease may occur. causes of immunodeficiency or immunosuppression may include, but are not limited to, primary or acquired immunodeficiency states, aids or other clinical manifestations of infection with human immunodeficiency

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - human papillomavirus type 6 l1 capsid protein antigen (unii: 61746o90dy) (human papillomavirus type 6 l1 capsid protein antigen - unii:61746o90dy), human papillomavirus type 11 l1 capsid protein antigen (unii: z845vhq61p) (human papillomavirus type 11 l1 capsid protein antigen - unii:z845vhq61p), human papillomavirus type 16 l1 capsid protein antigen (unii: 6lte2dnx63) (human papillomavirus type 16 l1 capsid protein antigen - unii:6lte2dnx63), human papillomavirus type 18 l1 capsid protein antigen (unii: - human papillomavirus type 6 l1 capsid protein antigen 20 ug in 0.5 ml - gardasil® is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by human papillomavirus (hpv) types included in the vaccine: - cervical, vulvar, vaginal, and anal cancer caused by hpv types 16 and 18 - genital warts (condyloma acuminata) caused by hpv types 6 and 11 and the following precancerous or dysplastic lesions caused by hpv types 6, 11, 16, and 18: - cervical intraepithelial neoplasia (cin) grade 2/3 and cervical adenocarcinoma in situ (ais) - cervical intraepithelial neoplasia (cin) grade 1 - vulvar intraepithelial neoplasia (vin) grade 2 and grade 3 - vaginal intraepithelial neoplasia (vain) grade 2 and grade 3 - anal intraepithelial neoplasia (ain) grades 1, 2, and 3 gardasil is indicated in boys and men 9 through 26 years of age for the prevention of the following diseases caused by hpv types included in the vaccine: - anal cancer caused by hpv types 16 and 18 - genital warts (condyloma acuminata) caused by hpv types 6 and